💡 Quick answer
The landmark clinical studies, treatment history and latest research for Finasteride — fact-checked and sourced.
Research & evidence
How treatment evolved
1992FDA approves finasteride 5 mg (Proscar), a type II 5-alpha-reductase inhibitor, for benign prostatic hyperplasia — establishing the molecule (Merck, MK-906) later repurposed at lower dose for hair loss.
1997FDA approves finasteride 1 mg (Propecia) on December 19, 1997 — the first oral drug approved for male androgenetic alopecia, based on Merck's pivotal Phase III program.
1998Publication of the landmark Phase III trials (Kaufman et al., Finasteride Male Pattern Hair Loss Study Group) in JAAD, providing the primary efficacy evidence underpinning the approval.
20085-year multinational extension data published (Kaufman et al., Eur J Dermatol), demonstrating sustained long-term benefit and a 93% relative reduction vs placebo in developing further visible hair loss.
2018Network meta-analysis (Gupta et al., JEADV) ranks finasteride among effective non-surgical treatments but formally grades the finasteride-vs-placebo evidence as 'very low' quality, signaling consensus on efficacy alongside limited trial quality.
Key clinical studies
Kaufman et al. (Finasteride Male Pattern Hair Loss Study Group), 19981998
Two 1-year double-blind RCTs, 1,553 men aged 18-41 with vertex MPHL; 1,215 continued into a blinded 2nd-year extension
Finasteride 1 mg/day increased hair count vs placebo by 107 hairs at 1 year and 138 hairs at 2 years in the 1-inch target area (both p<0.001); placebo patients showed progressive loss. Established efficacy for slowing loss and promoting regrowth.
Journal of the American Academy of Dermatology (JAAD), 39(4 Pt 1):578-589
Kaufman et al. (5-year multinational data), 20082008
Long-term analysis of the Phase III cohort, 1,553 men treated with finasteride 1 mg/day or placebo for up to 5 years
Over 5 years, finasteride 1 mg produced a 93% relative decrease vs placebo in the likelihood of developing further visible hair loss (95% CI 89-97%; p<0.001), with sustained benefit; placebo patients progressively worsened.
European Journal of Dermatology (Eur J Dermatol)
Gupta et al. (network meta-analysis), 20182018
Systematic review and network meta-analysis; 78 studies identified, 22 with usable data, covering finasteride, dutasteride, minoxidil, PRP and LLLT in androgenetic alopecia
Finasteride 1 mg was an effective treatment with mean hair-count change broadly comparable to other active options, but the authors graded the finasteride-vs-placebo evidence as 'very low' quality, underscoring the need for higher-quality RCTs.
Journal of the European Academy of Dermatology and Venereology (JEADV)
Latest research: Recent work (2023-2026) has shifted toward topical finasteride and low-dose oral combinations (e.g., finasteride plus low-dose oral or topical minoxidil) aimed at preserving efficacy while reducing systemic DHT suppression and sexual side effects; however, topical finasteride remains non-FDA-approved (compounded), and in April 2025 the FDA issued a safety communication on adverse events linked to compounded topical formulations, keeping the safety profile an active research and pharmacovigilance focus.
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
Explore more
Self-check →Treatments →Transplant →Women →New →Hair Loss Causes →Hair-Loss Glossary →Hair-Loss Questions & Answers →Hair-Loss Ingredient Evidence Ratings →Hair Transplant Cost by City →Research →Browse all →
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.
⚠️ When to see a doctor — don’t self-treat
- Sudden patchy or circular bald spots
- Redness, scaling, pus, pain or itch (possible scarring alopecia — treat urgently)
- Broken hairs or rapid loss
- Loss with body-wide signs (weight loss, fatigue, cycle changes, acne, extra hair)
- Loss right after a new medication
- Any hair loss in a child